Insieme di Insiemi: the new Italian campaign to inform and support women with ovarian cancer
A national mobilisation unites associations, clinicians and institutions to improve information, prevention and access to innovative treatments against ovarian cancer.
Key points
In Italia, 15 women are diagnosed with ovarian cancer every day. This carcinoma is still considered to be one of the 'big killers' among gynaecological neoplasms, with a 5-year survival rate of 43%, but with an increasing availability of innovative treatments.
In order to break the silence on the disease, strengthen awareness and bring ovarian cancer to the centre of public and institutional debate, a communication campaign dedicated to information, advocacy and mobilisation has been launched Insieme di Insiemi.
Conceived through the joint efforts of the MITO (Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies) and Mango (Mario Negri Gynecologic Oncology) groups with the patient associations ACTO Italia, LOTO, aBRCAcadabra, ALTo,
Never Alone and the clinicians and the non-binding support of Abbvie and Pharma&, the initiative was created to promote correct information on ovarian cancer, to give voice to the needs of patients, and to draw the attention of institutions to the need for more equitable, timely and appropriate treatment pathways.
Possible symptoms and the need for control
'Ovarian cancer is still associated with a high mortality rate, caused both by non-specific symptoms attributable to numerous pathologies, such as swelling or pelvic pain, and by the absence of dedicated screening that allows early diagnosis,' stressesSandro Pignata, Director of the Division of Medical Oncology of the Department of Uro-gynaecology at the National Cancer Institute of Naples and founder of the MITO Group. 'Only women with BRCA1 and BRCA2 alterations can benefit from preventive strategies thanks to genetic testing.

